Last reviewed · How we verify

Avelumab (MSB0010718C) — Competitive Intelligence Brief

Avelumab (MSB0010718C) (avelumab-msb0010718c) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

marketed Monoclonal antibody PD-L1 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Avelumab (MSB0010718C) (avelumab-msb0010718c) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Avelumab (MSB0010718C) TARGET avelumab-msb0010718c Pfizer marketed Monoclonal antibody PD-L1
DURVALUMAB DURVALUMAB marketed Programmed Death Ligand-1 Blocker [EPC] PD-L1 2017-01-01
AVELUMAB AVELUMAB marketed Programmed Death Ligand-1 Blocker [EPC] PD-L1 2017-01-01
Pf-06835375 pf-06835375 Pfizer marketed Immunotherapy PD-L1
Avelumab first-line maintenance Avelumab first-line maintenance Fondazione Policlinico Universitario Agostino Gemelli IRCCS marketed PD-L1 inhibitor PD-L1
Pf-06823859 pf-06823859 Pfizer marketed Monoclonal Antibody PD-1/PD-L1
Atezolizumab Injection [Tecentriq] Atezolizumab Injection [Tecentriq] Nykode Therapeutics ASA marketed PD-L1 inhibitor PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avelumab (MSB0010718C) — Competitive Intelligence Brief. https://druglandscape.com/ci/avelumab-msb0010718c. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: